Developer docs
API playgroundTry for free, no card

Search company profiles

RegCell

Full company profile

uuid0000kkt

Namestring
RegCell
Legal namestring
RegCell, Inc.
Websiteurl
regcellbio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

RegCell is a preclinical-stage biotechnology company developing regulatory T cell (Treg) therapies for autoimmune diseases and organ transplant rejection. The company was co-founded by Dr. Shimon Sakaguchi, the 2025 Nobel laureate credited with discovering Tregs in 1995, and operates a dual-base footprint with U.S. headquarters in Emeryville, California (established March 2025) and scientific operations in Osaka, Japan, anchored at Osaka University where Sakaguchi is a Distinguished Professor.

The company's core product is its Precision Epigenetic Reprogramming Platform, which converts conventional CD4+ T cells into stable, antigen-specific regulatory T cells (termed S/F-Epigen-Tregs) without requiring genetic modifications or viral DNA reagents. This is achieved by using small molecules to activate Foxp3 and re-establish Treg-specific epigenetic programs, generating cells that suppress only disease-driving immune responses rather than broadly suppressing immunity — the central limitation of current autoimmune therapies. The platform is covered by filed-pending patents on the S/F-Epigen-Treg manufacturing method and was validated in two November 2025 peer-reviewed publications in Science Translational Medicine showing efficacy in IBD, GVHD, and pemphigus vulgaris preclinical models. The lead indication is autoimmune hepatitis, with first-in-human trials targeted for 2025; additional addressable indications span rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn's disease, and ulcerative colitis.

RegCell has no commercial revenue and is funded by an oversubscribed $8.5M seed round (co-led by UTEC and FTI in March 2025, with Celadon, Mitsubishi UFJ Capital, OUVC, and Kyoto i-Cap participating) plus up to $37.3M in non-dilutive AMED V-ECO grant funding. It manufactures through a February 2026 CDMO partnership with Kincell Bio and employs 1-10 people. Revenue is intended to be generated through future therapeutic product sales and licensing of Treg cell therapies once clinical-stage assets receive regulatory approval; pricing and go-to-market details are not publicly disclosed at this stage.

Short descriptiontext

RegCell is a preclinical-stage biotech developing epigenetically reprogrammed regulatory T cell (S/F-Epigen-Treg) therapies to restore antigen-specific immune tolerance in autoimmune disease patients, founded by 2025 Nobel laureate Dr. Shimon Sakaguchi and headquartered in Emeryville, California.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Treg cell therapy, epigenetic cell reprogramming, autoimmune disease therapeutics, regulatory T cells, cell therapy platform
Industry1 code
PRIMARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Treg Cell Therapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Product Sales
TypeOne Time License
Description

RegCell plans to generate revenue through the development and commercialization of Treg cell therapies for autoimmune diseases and transplantation. The company is building toward first-in-human clinical trials targeting autoimmune indications.

regcellbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RegCell is a clinical-stage biotechnology company that develops Treg cell therapies using a proprietary epigenetic reprogramming platform. The platform converts patients' conventional CD4+ T cells into stable, antigen-specific regulatory T cells (S/F-Epigen-Tregs) without genetic modifications, targeting autoimmune diseases with autoimmune hepatitis as the lead clinical indication.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Stable Foxp3 expression and established Treg-specific epigenetic programs achieved in preclinical models
+2 more records
Product overview1 text field

RegCell offers a unified therapeutic platform centered on its Precision Epigenetic Reprogramming Platform, which generates S/F-Epigen-Tregs (Stable/Functional Epigenetically Reprogrammed Tregs). This technology converts a patient's own conventional T cells into antigen-specific regulatory T cells without requiring genetic modifications, simplifying manufacturing and enhancing safety. The company's lead Treg Cell Therapy targets autoimmune diseases, with its first clinical indication targeting autoimmune hepatitis. The platform addresses key limitations of current autoimmune treatments by providing disease-specific immune tolerance rather than broad immunosuppression.

Product and service2 records
1Treg Cell Therapy for Autoimmune Diseases
CategoryCell Therapy / Treg Cell Therapy
Description

A clinical-stage cell therapy that converts disease-causing T cells into protective regulatory T cells to treat autoimmune diseases by restoring immune tolerance rather than broadly suppressing the immune system. The lead indication is autoimmune hepatitis, with additional target indications including rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn's disease, ulcerative colitis, and prevention of organ transplant rejection.

2Precision Epigenetic Reprogramming Platform
CategoryCell Therapy Technology Platform
Description

Proprietary platform that epigenetically reprograms conventional CD4+ T cells into stable, antigen-specific regulatory T cells (S/F-Epigen-Tregs) without requiring genetic modifications or viral DNA reagents. Generates S/F-Epigen-Tregs with strong Foxp3 expression and established Treg-specific epigenetic programs for targeted immunosuppression to treat autoimmune diseases and prevent organ transplant rejection.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-10
Description

Kincell Bio, a U.S. cell therapy CDMO, partnered with RegCell to provide CMC development and GMP manufacturing support for RegCell's lead Treg program. The collaboration includes process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities to advance toward clinical trials.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage Treg cell therapy company developing antigen-specific regulatory T cells for autoimmune and inflammatory diseases. Directly comparable to RegCell on modality (Treg therapy), indication focus (autoimmune), and epigenetic/gene-editing strategies.

TypeDirect peer
Description

Cell therapy company developing engineered Treg therapies for autoimmune diseases and transplant rejection, with a lead program in liver transplant tolerance. Direct peer based on Treg modality, antigen-specific tolerance approach, and autoimmune/transplant indication overlap.

TypeDirect peer
Description

Clinical-stage CAR-Treg company developing cell therapies for autoimmune diseases including lupus and inflammatory bowel disease. Direct peer on cell therapy for autoimmune, though using engineered CAR-Treg rather than epigenetic reprogramming.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-Treg (restrained immune cells) therapies for autoimmune diseases. Direct peer based on cell therapy modality, autoimmune focus, and clinical-stage regulatory path.

5TeraImmune
TypeDirect peer
Description

Preclinical/early-clinical Treg cell therapy company developing antigen-specific regulatory T cells for autoimmune and inflammatory diseases. Direct peer on Treg modality and indication overlap, though slightly earlier in clinical translation.

TypeBroad incumbent
Description

Clinical-stage gene-editing company with broader cell therapy pipeline. Comparable as a larger, better-capitalized incumbent pursuing cell-based treatments where RegCell's epigenetic approach is a differentiated alternative to CRISPR-based strategies.

TypeBroad incumbent
Description

Clinical-stage gene editing and cell therapy company. Broader incumbent in cell and gene therapy space with significantly more capital and clinical maturity, making it a relevant comparator for modality risk and commercialization pathways.

TypeBroad incumbent
Description

Clinical-stage genomic medicine company with cell therapy and in vivo genome editing programs, including autoimmune applications. Broader incumbent providing a benchmark for cell therapy clinical execution and regulatory strategy.

TypeEmerging player
Description

Clinical-stage company developing iPSC-derived allogeneic cell therapies for autoimmune and oncology indications. Emerging player with overlapping cell therapy modality but distinct manufacturing and allogeneic approach.

TypeEmerging player
Description

Clinical-stage iPSC-derived cell therapy company with off-the-shelf NK and T-cell programs. Emerging player with partial overlap on cell therapy modality and cell engineering strategies relevant to RegCell's Treg manufacturing approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RegCell

Cell Therapy / Treg Cell Therapyregcellbio.com

RegCell is a preclinical-stage biotech developing epigenetically reprogrammed regulatory T cell (S/F-Epigen-Treg) therapies to restore antigen-specific immune tolerance in autoimmune disease patients, founded by 2025 Nobel laureate Dr. Shimon Sakaguchi and headquartered in Emeryville, California.

What RegCell does

RegCell is a preclinical-stage biotechnology company developing regulatory T cell (Treg) therapies for autoimmune diseases and organ transplant rejection. The company was co-founded by Dr. Shimon Sakaguchi, the 2025 Nobel laureate credited with discovering Tregs in 1995, and operates a dual-base footprint with U.S. headquarters in Emeryville, California (established March 2025) and scientific operations in Osaka, Japan, anchored at Osaka University where Sakaguchi is a Distinguished Professor.

The company's core product is its Precision Epigenetic Reprogramming Platform, which converts conventional CD4+ T cells into stable, antigen-specific regulatory T cells (termed S/F-Epigen-Tregs) without requiring genetic modifications or viral DNA reagents. This is achieved by using small molecules to activate Foxp3 and re-establish Treg-specific epigenetic programs, generating cells that suppress only disease-driving immune responses rather than broadly suppressing immunity — the central limitation of current autoimmune therapies. The platform is covered by filed-pending patents on the S/F-Epigen-Treg manufacturing method and was validated in two November 2025 peer-reviewed publications in Science Translational Medicine showing efficacy in IBD, GVHD, and pemphigus vulgaris preclinical models. The lead indication is autoimmune hepatitis, with first-in-human trials targeted for 2025; additional addressable indications span rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn's disease, and ulcerative colitis.

RegCell has no commercial revenue and is funded by an oversubscribed $8.5M seed round (co-led by UTEC and FTI in March 2025, with Celadon, Mitsubishi UFJ Capital, OUVC, and Kyoto i-Cap participating) plus up to $37.3M in non-dilutive AMED V-ECO grant funding. It manufactures through a February 2026 CDMO partnership with Kincell Bio and employs 1-10 people. Revenue is intended to be generated through future therapeutic product sales and licensing of Treg cell therapies once clinical-stage assets receive regulatory approval; pricing and go-to-market details are not publicly disclosed at this stage.

RegCell firmographics

Firmographics
Name
RegCell
Legal name
RegCell, Inc.
Website
https://regcellbio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
RegCell is a preclinical-stage biotech developing epigenetically reprogrammed regulatory T cell (S/F-Epigen-Treg) therapies to restore antigen-specific immune tolerance in autoimmune disease patients, founded by 2025 Nobel laureate Dr. Shimon Sakaguchi and headquartered in Emeryville, California.
Ownership category
akta.pro rank

RegCell industry classification

Industry
Product category
Cell Therapy / Treg Cell Therapy
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Treg cell therapy
  • Epigenetic cell reprogramming
  • Autoimmune disease therapeutics
  • Regulatory T cells
  • Cell therapy platform

Where RegCell is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

RegCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Therapeutic Product Sales: RegCell plans to generate revenue through the development and commercialization of Treg cell therapies for autoimmune diseases and transplantation. The company is building toward first-in-human clinical trials targeting autoimmune indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

RegCell product offering

Product offering

Core offering

RegCell is a clinical-stage biotechnology company that develops Treg cell therapies using a proprietary epigenetic reprogramming platform. The platform converts patients' conventional CD4+ T cells into stable, antigen-specific regulatory T cells (S/F-Epigen-Tregs) without genetic modifications, targeting autoimmune diseases with autoimmune hepatitis as the lead clinical indication.

Product overview

RegCell offers a unified therapeutic platform centered on its Precision Epigenetic Reprogramming Platform, which generates S/F-Epigen-Tregs (Stable/Functional Epigenetically Reprogrammed Tregs). This technology converts a patient's own conventional T cells into antigen-specific regulatory T cells without requiring genetic modifications, simplifying manufacturing and enhancing safety. The company's lead Treg Cell Therapy targets autoimmune diseases, with its first clinical indication targeting autoimmune hepatitis. The platform addresses key limitations of current autoimmune treatments by providing disease-specific immune tolerance rather than broad immunosuppression.

Differentiator

Problem solved

Functional benefit

Products and services

  • Treg Cell Therapy for Autoimmune Diseases A clinical-stage cell therapy that converts disease-causing T cells into protective regulatory T cells to treat autoimmune diseases by restoring immune tolerance rather than broadly suppressing the immune system. The lead indication is autoimmune hepatitis, with additional target indications including rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, lupus, Crohn's disease, ulcerative colitis, and prevention of organ transplant rejection.
  • Precision Epigenetic Reprogramming Platform Proprietary platform that epigenetically reprograms conventional CD4+ T cells into stable, antigen-specific regulatory T cells (S/F-Epigen-Tregs) without requiring genetic modifications or viral DNA reagents. Generates S/F-Epigen-Tregs with strong Foxp3 expression and established Treg-specific epigenetic programs for targeted immunosuppression to treat autoimmune diseases and prevent organ transplant rejection.

Quantifiable outcome

  • Stable Foxp3 expression and established Treg-specific epigenetic programs achieved in preclinical models
  • +2 more outcomes

Companies that use RegCell

Customer profile

Segments1 record

Ideal customer profiles1 record

RegCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RegCell partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kincell BiocoreImplementation/ SI/ Consulting Partner · 10 February 2026Kincell Bio, a U.S. cell therapy CDMO, partnered with RegCell to provide CMC development and GMP manufacturing support for RegCell's lead Treg program. The collaboration includes process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities to advance toward clinical trials.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

RegCell competitors and assessment

Company assessment

Direct peers

  • Sonoma Biotherapeutics: Clinical-stage Treg cell therapy company developing antigen-specific regulatory T cells for autoimmune and inflammatory diseases. Directly comparable to RegCell on modality (Treg therapy), indication focus (autoimmune), and epigenetic/gene-editing strategies.
  • Quell Therapeutics: Cell therapy company developing engineered Treg therapies for autoimmune diseases and transplant rejection, with a lead program in liver transplant tolerance. Direct peer based on Treg modality, antigen-specific tolerance approach, and autoimmune/transplant indication overlap.
  • Kyverna Therapeutics: Clinical-stage CAR-Treg company developing cell therapies for autoimmune diseases including lupus and inflammatory bowel disease. Direct peer on cell therapy for autoimmune, though using engineered CAR-Treg rather than epigenetic reprogramming.
  • Cabaletta Bio: Clinical-stage cell therapy company developing CAR-Treg (restrained immune cells) therapies for autoimmune diseases. Direct peer based on cell therapy modality, autoimmune focus, and clinical-stage regulatory path.
  • TeraImmune: Preclinical/early-clinical Treg cell therapy company developing antigen-specific regulatory T cells for autoimmune and inflammatory diseases. Direct peer on Treg modality and indication overlap, though slightly earlier in clinical translation.

Broad incumbents

  • CRISPR Therapeutics: Clinical-stage gene-editing company with broader cell therapy pipeline. Comparable as a larger, better-capitalized incumbent pursuing cell-based treatments where RegCell's epigenetic approach is a differentiated alternative to CRISPR-based strategies.
  • Editas Medicine: Clinical-stage gene editing and cell therapy company. Broader incumbent in cell and gene therapy space with significantly more capital and clinical maturity, making it a relevant comparator for modality risk and commercialization pathways.
  • Sangamo Therapeutics: Clinical-stage genomic medicine company with cell therapy and in vivo genome editing programs, including autoimmune applications. Broader incumbent providing a benchmark for cell therapy clinical execution and regulatory strategy.

Emerging players

  • Century Therapeutics: Clinical-stage company developing iPSC-derived allogeneic cell therapies for autoimmune and oncology indications. Emerging player with overlapping cell therapy modality but distinct manufacturing and allogeneic approach.
  • Fate Therapeutics: Clinical-stage iPSC-derived cell therapy company with off-the-shelf NK and T-cell programs. Emerging player with partial overlap on cell therapy modality and cell engineering strategies relevant to RegCell's Treg manufacturing approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights7 records

Customer concentration

RegCell social profiles

Digital presence

RegCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RegCell leadership team

Management profile

Number of profiles

Profiles6 records

RegCell funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RegCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RegCell

What does RegCell do?

RegCell is a clinical-stage biotechnology company that develops Treg cell therapies using a proprietary epigenetic reprogramming platform. The platform converts patients' conventional CD4+ T cells into stable, antigen-specific regulatory T cells (S/F-Epigen-Tregs) without genetic modifications, targeting autoimmune diseases with autoimmune hepatitis as the lead clinical indication.

Is RegCell a public or private company?

RegCell is a private company. It is classified as venture growth investor backed and is currently operating.

When was RegCell founded?

RegCell was founded in 2023. It employs 11 to 50 people.

Where is RegCell based?

RegCell is headquartered in Emeryville, United States, in the North America region.

How does RegCell make money?

One revenue line is on record: therapeutic Product Sales.

Who are RegCell's main competitors?

Direct peers on record are Sonoma Biotherapeutics, Quell Therapeutics, Kyverna Therapeutics, Cabaletta Bio and TeraImmune. Broad incumbents are CRISPR Therapeutics, Editas Medicine and Sangamo Therapeutics. Emerging players are Century Therapeutics and Fate Therapeutics.

Does RegCell have an API?

No public API is recorded for RegCell.

What industry is RegCell in?

RegCell's product category is Cell Therapy / Treg Cell Therapy. Its primary akta.pro industry code is HLAAABAK, Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingGlobal Brain makes additional investment in RegCellGlobal Brain made an additional private investment in RegCell, a biotech developing epigenetic regulatory T-cell reprogramming therapies for autoimmune diseases. The funding came via Global Brain Flagship Fund IX and 321FORCE Global Innovation Fund L.P. RegCell plans an IND filing alongside Phase 2 proof-of-concept studies across two autoimmune indications.citybizNobel Laureate Sakaguchi’s RegCell Secures $66M to Push Smart ImmunosuppressantsRegCell, led by Nobel laureate Shimon Sakaguchi, closed a $44 million Series A led by Playground Global and a $22 million grant from Japan's AMED. The funding will advance its epigenetic reprogramming platform into clinical-stage development for autoimmune diseases. The company aims to establish proof of concept and expand across indications.VC News DailyRegCell Receives $44M Series A RoundRegCell closed a fully subscribed $44M Series A led by Playground Global, plus a $22M grant from Japan's AMED, totaling $66M. The funding will advance its epigenetic reprogramming platform for autoimmune diseases into clinical-stage development. Jory Bell will join the board.Venture Capital Access OnlineRegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the ClinicRegCell closed a $44 million Series A led by Playground Global and received a $22 million AMED grant, totaling $66 million. The funding will advance its epigenetic reprogramming platform into clinical-stage development across autoimmune indications, including a Phase 2 proof-of-concept study.BioSpaceKincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune DiseasesKincell Bio, a U.S. cell therapy contract development and manufacturing organization (CDMO), announced a new collaboration with biotechnology company RegCell to advance RegCell's lead regulatory T cell (Treg) therapy program toward clinical trials for autoimmune diseases. Under the partnership, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support, including process transfer, scalable manufacturing optimization, and clinical material supply for IND-enabling activities. RegCell's platform, founded on the work of Nobel laureate Professor Shimon Sakaguchi, converts disease-driving T cells into lineage-stable Tregs without requiring gene editing or viral DNA reagents, potentially reducing manufacturing complexity.PharmiWeb.comKincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune DiseasesKincell Bio, a U.S. cell therapy contract development and manufacturing organization (CDMO), announced a collaboration with RegCell, a biotechnology company developing Treg cell therapies for autoimmune diseases. Under the partnership, Kincell Bio will provide CMC development and GMP manufacturing support to accelerate RegCell's lead Treg program toward clinical trials, including process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities. RegCell's platform is based on epigenetically reprogrammed regulatory T cells developed by co-founder Professor Shimon Sakaguchi, the 2025 Nobel Prize laureate in Physiology or Medicine, and does not require gene editing or viral DNA reagents, simplifying manufacturing complexity.The Japan TimesNobel winner Shimon Sakaguchi aims for effective cancer treatment - The Japan TimesNobel Prize winner Shimon Sakaguchi announced plans to develop effective cancer immunotherapy using regulatory T cells, for which he established the startup RegCell in the United States. Clinical trials for autoimmune diseases are expected to begin next year, with future goals focused on preventing cancer metastasis through oral drugs that manipulate immune responses.PR NewswireRegCell Announces Two Peer-Reviewed Publications Supporting its Robust Scientific Foundation on Antigen-Specific Tolerance to Treat Autoimmune DiseasesRegCell, Inc. announced two peer-reviewed studies published in Science Translational Medicine from its scientific founder Shimon Sakaguchi, demonstrating for the first time the production of stable, antigen-specific regulatory T cells (Tregs) from pathogenic T cells using epigenetic reprogramming. The studies showed successful conversion of disease-causing T cells into stable Tregs that selectively suppressed autoimmune responses in mouse models of inflammatory bowel disease, graft-versus-host disease, and pemphigus vulgaris without causing systemic immunosuppression. The findings provide scientific validation for RegCell's proprietary platform approach to treating autoimmune diseases by restoring antigen-specific immune tolerance.FierceBiotechIn 2 papers, Nobel winner debuts technique to turn rogue T cells into their own treatmentNobel laureate Shimon Sakaguchi and colleagues published two papers in Science Translational Medicine demonstrating a technique to convert rogue T cells that attack the body into regulatory T cells (Tregs) that suppress autoimmune diseases, using a small molecule to activate the Foxp3 gene while blocking the CD28 receptor. The approach successfully treated inflammatory bowel disease, graft-versus-host disease, and pemphigus vulgaris in mice, and converted human T cells into Tregs in laboratory experiments. RegCell, a company spun out of Sakaguchi's lab at Osaka University, plans first-in-human clinical trials of the technique.PrtimesDr. Shibumi Sakaguchi, the founder and director of RegCell, Inc., which is an investment of Global Brain, has been awarded the Nobel Prize in Physiology or Medicine.RegCell, Inc. founder and director Dr. Shimon Sakaguchi has been awarded the Nobel Prize in Physiology or Medicine for his 1995 discovery of regulatory T cells (Treg), which fundamentally overturned understanding of immune tolerance—the mechanism that prevents the immune system from attacking the body. RegCell, established in Kyoto in 2016 and now headquartered in the United States, is advancing clinical trials for autoimmune diseases using a proprietary cell therapy platform that converts a patient's own T cells into disease-antigen-specific Tregs. The company was backed by Global Brain Corporation through its Global Brain 9th Fund and 321FORCE™ investment vehicle.